Neuroprotective Efficacy of Prophylactic Enteral and Parenteral Nimodipine Treatment in Vestibular Schwannoma Surgery: A Comparative Study

Abstract

Background and Study Aims/Object Oral nimodipine improves neurologic outcome after aneurysmal subarachnoid hemorrhage. In addition, the neuroprotective efficacy of nimodipine has been revealed following skull base, laryngeal, and maxillofacial surgery. Pharmacokinetic investigations showed nimodipine to reach higher serum levels following parenteral versus enteral administration. Furthermore, a correlation between nimodipine levels in serum, cerebrospinal fluid, and nerve tissue could be quantified. These observations raise the question whether the proven neuroprotective effect of nimodipine is related to its serum level.

Patients/Material and Methods A consecutive series of 37 patients with vestibular schwannoma treated with nimodipine from the day before surgery until the seventh postoperative day was analyzed retrospectively. Both groups received standard dosages for enteral (n = 17) and parenteral (n = 20) nimodipine medication. Nimodipine levels were measured in pre- and postoperative serum and cerebrospinal fluid samples. Cochlear and facial nerve functions were documented before surgery, in the early postoperative course, and 1 year after surgery.

Results Facial nerve outcome was significantly better in the group with parenteral nimodipine medication (p = 0.038). Logistical regression analysis revealed a seven times smaller risk for a deterioration of facial nerve function in the group with parenteral treatment. There was no difference in hearing preservation between both groups despite tumor size tending to be larger in the parenteral group. Intraoperative (p = 0.004), postoperative (p = 0.001), and serum and cerebrospinal fluid (p = 0.024) nimodipine levels were significantly higher following parenteral administration as compared with enteral administration. Both groups were comparable regarding tumor size and extent of resection.

Conclusions These results support a dependency of nimodipine's neuroprotective efficacy on its serum levels. Parenteral nimodipine treatment produces higher serum levels and has a higher neuroprotective potency in vestibular schwannoma surgery compared with enteral treatment.

Keywords

nimodipine - neuroprotection - vestibular schwannoma - subarachnoid hemorrhage

• References

• 1 Bederson JB, Connolly Jr ES, Batjer HH , et al; American Heart Association. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 2009; 40 (3) 994-1025
• 2 Dorhout Mees SM, Rinkel GJ, Feigin VL , et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. [review]. Cochrane Database Syst Rev 2007; (3) CD000277
• 3 Pickard JD, Murray GD, Illingworth R , et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 1989; 298 (6674) 636-642
• 4 Rabinstein AA, Lanzino G, Wijdicks EF. Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage. Lancet Neurol 2010; 9 (5) 504-519
• 5 Angelov DN, Neiss WF, Streppel M, Andermahr J, Mader K, Stennert E. Nimodipine accelerates axonal sprouting after surgical repair of rat facial nerve. J Neurosci 1996; 16 (3) 1041-1048
• 6 Guntinas-Lichius O, Martinez-Portillo F, Lebek J, Angelov DN, Stennert E, Neiss WF. Nimodipine maintains in vivo the increase in GFAP and enhances the astroglial ensheathment of surviving motoneurons in the rat following permanent target deprivation. J Neurocytol 1997; 26 (4) 241-248
• 7 Kansu L, Ozkarakas H, Efendi H, Okar I. Protective effects of pentoxifylline and nimodipine on acoustic trauma in Guinea pig cochlea. Otol Neurotol 2011; 32 (6) 919-925
• 8 Lindsay RW, Heaton JT, Edwards C, Smitson C, Hadlock TA. Nimodipine and acceleration of functional recovery of the facial nerve after crush injury. Arch Facial Plast Surg 2010; 12 (1) 49-52
• 9 Mattsson P, Aldskogius H, Svensson M. Nimodipine-induced improved survival rate of facial motor neurons following intracranial transection of the facial nerve in the adult rat. J Neurosurg 1999; 90 (4) 760-765
• 10 Mattsson P, Janson AM, Aldskogius H, Svensson M. Nimodipine promotes regeneration and functional recovery after intracranial facial nerve crush. J Comp Neurol 2001; 437 (1) 106-117
• 11 Bischoff B, Romstöck J, Fahlbusch R, Buchfelder M, Strauss C. Intraoperative brainstem auditory evoked potential pattern and perioperative vasoactive treatment for hearing preservation in vestibular schwannoma surgery. J Neurol Neurosurg Psychiatry 2008; 79 (2) 170-175
• 12 Scheller C, Strauss C, Fahlbusch R, Romstöck J. Delayed facial nerve paresis following acoustic neuroma resection and postoperative vasoactive treatment. Zentralbl Neurochir 2004; 65 (3) 103-107
• 13 Scheller C, Richter HP, Engelhardt M, Köenig R, Antoniadis G. The influence of prophylactic vasoactive treatment on cochlear and facial nerve functions after vestibular schwannoma surgery: a prospective and open-label randomized pilot study. Neurosurgery 2007; 61 (1) 92-97 ; discussion 97–98
• 14 Strauss C, Bischoff B, Neu M, Berg M, Fahlbusch R, Romstöck J. Vasoactive treatment for hearing preservation in acoustic neuroma surgery. J Neurosurg 2001; 95 (5) 771-777
• 15 Strauss C, Romstöck J, Fahlbusch R, Rampp S, Scheller C. Preservation of facial nerve function after postoperative vasoactive treatment in vestibular schwannoma surgery. Neurosurgery 2006; 59 (3) 577-584 ; discussion 577–584
• 16 Hydman J, Remahl S, Björck G, Svensson M, Mattsson P. Nimodipine improves reinnervation and neuromuscular function after injury to the recurrent laryngeal nerve in the rat. Ann Otol Rhinol Laryngol 2007; 116 (8) 623-630
• 17 Mattsson P, Björck G, Remahl S , et al. Nimodipine and microsurgery induced recovery of the vocal cord after recurrent laryngeal nerve resection. Laryngoscope 2005; 115 (10) 1863-1865
• 18 Scheller K, Scheller C. Nimodipine promotes regeneration of peripheral facial nerve function after traumatic injury following maxillofacial surgery: an off label pilot-study. J Craniomaxillofac Surg 2012; 40 (5) 427-434
• 19 Rämsch KD, Ahr G, Tettenborn D, Auer LM. Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage. Neurochirurgia (Stuttg) 1985; 28 (Suppl. 01) 74-78
• 20 Soppi V, Kokki H, Koivisto T , et al. Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage—a pilot study. Eur J Clin Pharmacol 2007; 63 (4) 355-361
• 21 Scheller C, Vogel AS, Simmermacher S , et al. Prophylactic intravenous nimodipine treatment in skull base surgery: pharmacokinetic aspects. J Neurol Surg A Cent Eur Neurosurg 2012; 73 (3) 153-159
• 22 Scheller C, Wienke A, Wurm F , et al. Enteral or parenteral nimodipine treatment: a comparative pharmacokinetic study. J Neurol Surg A Cent Eur Neurosurg 2013; ; March 15 ( Epub ahead of print)
• 23 Koos WT. Criteria for preservation of vestibulocochlear nerve function during microsurgical removal of acoustic neurinomas. Acta Neurochir (Wien) 1988; 92 (1–4) 55-66
• 24 House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg 1985; 93 (2) 146-147
• 25 Anonymous Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology-Head and Neck Surgery Foundation, INC. Otolaryngol Head Neck Surg 1995; 113 (3) 179-180
• 26 Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F. Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypertens 2008; 30 (8) 744-766
• 27 Dreier JP, Windmüller O, Petzold G, Lindauer U, Einhäupl KM, Dirnagl U. Ischemia triggered by red blood cell products in the subarachnoid space is inhibited by nimodipine administration or moderate volume expansion/hemodilution in rats. Neurosurgery 2002; 51 (6) 1457-1465 ; discussion 1465–1467
• 28 Langley MS, Sorkin EM. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs 1989; 37 (5) 669-699
• 29 Castanares-Zapatero D, Hantson P. Pharmacological treatment of delayed cerebral ischemia and vasospasm in subarachnoid hemorrhage. Ann Intensive Care 2011; 1 (1) 12
• 30 Allen GS, Ahn HS, Preziosi TJ , et al. Cerebral arterial spasm—a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med 1983; 308 (11) 619-624
• 31 Vinge E, Andersson KE, Brandt L, Ljunggren B, Nilsson LG, Rosendal-Helgesen S. Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. Eur J Clin Pharmacol 1986; 30 (4) 421-425
• 32 Kronvall E, Undrén P, Romner B, Säveland H, Cronqvist M, Nilsson OG. Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration. J Neurosurg 2009; 110 (1) 58-63
• 33 Soppi V, Karamanakos PN, Koivisto T , et al. A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage. World Neurosurg 2012; 78 (1–2) 101-109
• 34 Hänggi D, Perrin J, Eicker S , et al. Local delivery of nimodipine by prolonged-release microparticles—feasibility, effectiveness and dose-finding in experimental subarachnoid hemorrhage. PLoS ONE 2012; 7 (9) e42597
• 35 Vergouwen MD, Vermeulen M, Roos YB. Effect of nimodipine on outcome in patients with traumatic subarachnoid haemorrhage: a systematic review. Lancet Neurol 2006; 5 (12) 1029-1032
• 36 Pillai SV, Kolluri VR, Mohanty A, Chandramouli BA. Evaluation of nimodipine in the treatment of severe diffuse head injury: a double-blind placebo-controlled trial. Neurol India 2003; 51 (3) 361-363
• 37 Bailey I, Bell A, Gray J , et al. A trial of the effect of nimodipine on outcome after head injury. Acta Neurochir (Wien) 1991; 110 (3–4) 97-105
• 38 The European Study Group on Nimodipine in Severe Head Injury. A multicenter trial of the efficacy of nimodipine on outcome after severe head injury. J Neurosurg 1994; 80 (5) 797-804
• 39 Harders A, Kakarieka A, Braakman R. Traumatic subarachnoid hemorrhage and its treatment with nimodipine. German tSAH Study Group. J Neurosurg 1996; 85 (1) 82-89
• 40 The American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke. Stroke 1992; 23 (1) 3-8
• 41 Zhang J, Yang J, Zhang C, Jiang X, Zhou H, Liu M. Calcium antagonists for acute ischemic stroke. [review]. Cochrane Database Syst Rev 2012; 5: CD001928
• 42 Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 2009; 40 (3, Suppl): S111-S114
• 43 Horn J, de Haan RJ, Vermeulen M, Limburg M. Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke 2001; 32 (2) 461-465
• 44 Lecht S, Rotfeld E, Arien-Zakay H , et al. Neuroprotective effects of nimodipine and nifedipine in the NGF-differentiated PC12 cells exposed to oxygen-glucose deprivation or trophic withdrawal. Int J Dev Neurosci 2012; 30 (6) 465-469
• 45 Ferenz KB, Gast RE, Rose K, Finger IE, Hasche A, Krieglstein J. Nerve growth factor and brain-derived neurotrophic factor but not granulocyte colony-stimulating factor, nimodipine and dizocilpine, require ATP for neuroprotective activity after oxygen-glucose deprivation of primary neurons. Brain Res 2012; 1448: 20-26